Insight, China's Pharmaceutical Industry

Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

China’s National Health Commission (NHC) issued the “Work Procedures for Evaluating the Clinical Application of...

Company Medical Device

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

Fineline Cube Mar 20, 2026

Medtronic plc (NYSE: MDT) announced the first clinical implantation of its Penditure left atrial appendage...

Company Drug

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

Fineline Cube Mar 20, 2026

3SBio Inc. (HKG: 1530) announced that China’s National Medical Products Administration (NMPA) has approved SSS06,...

Company Drug

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

Fineline Cube Mar 20, 2026

Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for...

Company Drug

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda

Fineline Cube Mar 20, 2026

Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region...

Company

Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence

Fineline Cube Mar 20, 2026

Sanofi S.A. (NASDAQ: SNY) has officially opened its China Innovation and Operations Hub in Chengdu,...

Company

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market

Fineline Cube Mar 20, 2026

AstraZeneca PLC (NASDAQ: AZN) has signed a Memorandum of Understanding with the Guangzhou Economic and...

Company Drug

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial

Fineline Cube Mar 20, 2026

Novo Nordisk A/S (NYSE: NVO) announced FDA approval of Wegovy HD (semaglutide) 7.2 mg injection,...

Company Drug

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Fineline Cube Mar 20, 2026

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...

Company Drug

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Fineline Cube Mar 20, 2026

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating...

Others

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Fineline Cube Mar 20, 2026

Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...

Company Deals

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Fineline Cube Mar 20, 2026

Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube Mar 19, 2026

Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that ABSK061 received Orphan Drug Designation (ODD) from...

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Fineline Cube Mar 19, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical...

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Fineline Cube Mar 19, 2026

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate...

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube Mar 19, 2026

InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced FDA clearance to initiate a Phase II clinical...

Company Drug

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Fineline Cube Mar 19, 2026

Suzhou Kintor Pharmaceuticals, Inc. (HKG: 9939) announced that its pivotal Phase III clinical study for...

Medical Device

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

Fineline Cube Mar 19, 2026

Super Vision Technology, Inc. announced National Medical Products Administration (NMPA) approval for its implantable ocular...

Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026

GE HealthCare (NASDAQ: GEHC) announced completion of the acquisition of Intelerad, a leading medical imaging...

Company Deals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Fineline Cube Mar 19, 2026

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, announced a...

Insight, China's Pharmaceutical Industry

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda

Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence

AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market

Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial

Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy

Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

You Missed

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China